Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE140440 | DU145 and PCÂ cell lines | Cell line | Prostate cancer | Prostate cancer | Chemotherapy | docetaxel | NA | Malignant cells | 2.20039 | 1.05e-11 |
GSE131984_Pac | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | NA | Malignant cells | 0.306202 | 3.12e-07 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | cDCs | 0.260795 | 3.07e-02 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | Mono/Macro | 0.336038 | 2.13e-17 |
GSE164551 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Immunotherapy | CAR-T | NA | Mono/Macro | -0.424434 | 8.25e-21 |
GSE207422_Sin | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Mono/Macro | 0.519494 | 3.54e-08 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | Malignant cells | -0.250971 | 0.00e+00 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | cDCs | -0.282936 | 2.43e-13 |
GSE131984_JQ1 | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 | NA | Malignant cells | 0.845837 | 0.00e+00 |
GSE131984_JQ1Pac | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + paclitaxel | NA | Malignant cells | 1.20789 | 0.00e+00 |
GSE131984_JQ1Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + palbociclib | NA | Malignant cells | 1.65459 | 0.00e+00 |
GSE131984_Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | palbociclib | NA | Malignant cells | 1.24474 | 0.00e+00 |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib | NA | Malignant cells | 1.17828 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
TGFBI | kznf__ZNF594_Schmitges2016_RCADE | ZNF594 (directAnnotation). |
TGFBI | metacluster_22.19 | NFE2 (directAnnotation). |
TGFBI | metacluster_22.37 | BACH1 (directAnnotation). |
TGFBI | metacluster_22.36 | BACH2 (directAnnotation). |
TGFBI | metacluster_22.20 | MAFG (directAnnotation). |
TGFBI | metacluster_22.16 | BACH2 (directAnnotation). |
TGFBI | kznf__ZNF384_Schmitges2016_RCADE | ZNF384 (directAnnotation). |
TGFBI | metacluster_22.11 | NFE2 (directAnnotation). |
TGFBI | metacluster_22.13 | MAFK (inferredBy_Orthology). |
TGFBI | jaspar__MA1125.1 | ZNF384 (directAnnotation). |
TGFBI | metacluster_22.32 | NFE2L2 (directAnnotation). |
TGFBI | metacluster_32.24 | ZNF287 (directAnnotation). |
TGFBI | metacluster_22.39 | NFE2L2 (directAnnotation). |
TGFBI | metacluster_22.21 | NFE2L2 (inferredBy_Orthology). |
TGFBI | metacluster_22.17 | NFE2 (directAnnotation). |
TGFBI | metacluster_30.4 | BACH1; BACH1; MAFG; MAFG; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2 (directAnnotation). |
TGFBI | metacluster_22.12 | NFE2; NFE2L1 (directAnnotation). |
TGFBI | metacluster_22.25 | NFE2L2 (directAnnotation). |
TGFBI | transfac_pro__M05770 | ZNF77 (directAnnotation). |
TGFBI | metacluster_22.1 | MAFF (inferredBy_Orthology). |
TGFBI | metacluster_187.7 | FEZF1; FEZF1; ZNF384; ZNF384; ZNF384 (directAnnotation). OVOL2; OVOL3; PEG3; PLAG1; PLAGL1; PLAGL2; REST; SCAND1; ZKSCAN2; ZNF131; ZNF174; ZNF18; ZNF202; ZNF274; ZNF444; ZNF446; ZNF496; ZNF518A; ZNF518B; ZNF576; ZNF641; ZNF770; ZSCAN1; ZSCAN18; ZSCAN29; ZSCAN32; ZSCAN5A; ZSCAN5B; ZSCAN5C (inferredBy_Orthology). |
TGFBI | metacluster_155.30 | ZNF254 (directAnnotation). |
TGFBI | kznf__KLF1_Barrera2016.2_PBM | KLF1 (directAnnotation). |
TGFBI | taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr | ELF1; MEIS1 (directAnnotation). |
TGFBI | taipale_tf_pairs__HOXD12_ELK3_NTTTAYNNCCGGAARNN_CAP_repr | ELK3; HOXD12 (directAnnotation). |
TGFBI | metacluster_81.7 | CREB1 (directAnnotation). |
TGFBI | metacluster_134.7 | FOXD2; FOXG1; FOXI1; FOXJ2; FOXJ2; FOXJ3; FOXJ3; FOXK1; FOXK1; FOXK2; FOXO4; FOXO6; FOXP2 (directAnnotation). FOXC1; FOXO1; FOXO6 (inferredBy_Orthology). |
TGFBI | metacluster_157.2 | ATF3; ATF3; ATF3; BACH1; BACH1; BACH1; BACH2; BACH2; BACH2; BACH2; BATF; BATF; BCL11A; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JDP2; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; JUND; MAF; MAFB; MAFF; MAFG; MAFK; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2; NFE2L1; NFE2L1; NFE2L2; NFE2L3; ZNF3; ZSCAN5C (directAnnotation). FOSL1; JUN; JUN; JUN; JUNB; JUNB; JUND (inferredBy_Orthology). |
TGFBI | transfac_pro__M05706 | ZNF20 (directAnnotation). |
TGFBI | transfac_pro__M05749 | ZNF470 (directAnnotation). |
TGFBI | metacluster_72.11 | ZNF430 (directAnnotation). |
TGFBI | taipale_tf_pairs__FLI1_CEBPD_RNCGGANNTTGCGCAAN_CAP | CEBPD; FLI1 (directAnnotation). |
TGFBI | transfac_pro__M05721 | ZNF235 (directAnnotation). |
TGFBI | transfac_pro__M06800 | ZBTB22 (inferredBy_Orthology). |
TGFBI | metacluster_187.8 | ZNF22 (directAnnotation). |
TGFBI | cisbp__M00196 | BBX (inferredBy_Orthology). |
TGFBI | jaspar__MA1944.1 | ETV5 (directAnnotation). |
TGFBI | tfdimers__MD00186 | NFATC3; SPI1 (directAnnotation). |
TGFBI | transfac_pro__M06678 | ZNF287 (inferredBy_Orthology). |
TGFBI | transfac_pro__M05972 | ZNF701 (directAnnotation). |
TGFBI | jaspar__MA0702.2 | LMX1A (directAnnotation). |
TGFBI | taipale_tf_pairs__ELK1_HOXA1_RCCGGAAGTAATTA_HT | ELK1; HOXA1 (directAnnotation). |
TGFBI | hdpi__FLI1 | FLI1 (directAnnotation). |
TGFBI | taipale_tf_pairs__HOXB2_ELK3_RSCGGAAGTMRTTA_CAP | ELK3; HOXB2 (directAnnotation). |
TGFBI | taipale_tf_pairs__ELK1_EOMES_TNRCACCGGAAGN_CAP | ELK1; EOMES (directAnnotation). |
TGFBI | taipale_tf_pairs__ETV2_DRGX_RSCGGAWRYATTA_CAP_repr | DRGX; ETV2 (directAnnotation). |
TGFBI | jaspar__MA1957.1 | ELK1 (directAnnotation). |
TGFBI | taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGTMATTA_CAP_repr | ETV2; HOXA2 (directAnnotation). |
TGFBI | taipale_tf_pairs__ELK1_TBX21_TNRCACCGGAAGNN_CAP_repr | ELK1; TBX21 (directAnnotation). |
TGFBI | taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP | ELF1; HOXB2 (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |